I think this is spot on.. Farrell - increase the margins now and exploit the competetive advantage...from Bloomberg"Betting against the device stocks has been profitable for short-sellers this quarter. Paper profits for bearish bettors on the handful of stocks — Insulet, Tandem Diabetes Care Inc., ResMed and Dexcom — were roughly $1 billion in the third quarter through Thursday’s close, according to data from S3 Partners LLC’s Ihor Dusaniwsky.
More news await these stocks as Lilly’s tirzepatide — already approved for diabetes as Mounjaro — is expected to enter the weight-loss market with an approval for obesity expected by the end of the year. Additional trial results showing the benefits of the weight-loss drugs are expected in the next six to 18 months and positive data could add more pummeling to these diabetes and insulin pump stocks, Johnson said.
The best case scenario for these diabetes stocks, according to BI’s Henriksson, is for the companies to post third-quarter earnings “that shows that it’s business as usual.”
I think this is spot on.. Farrell - increase the margins now and...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.78 |
Change
-0.320(0.97%) |
Mkt cap ! $20.91B | |||
| Open | High | Low | Value | Volume |
| $32.74 | $33.07 | $32.74 | $34.25M | 1.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1267 | $32.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.82 | 2077 | 2 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.87 |
Change
-0.320 ( 0.67 %) |
||||
| Open | High | Low | Volume | ||
| $32.77 | $33.07 | $32.77 | 531228 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| RMD (ASX) Chart |